Capital Research Global Investors Buys 108,556 Shares of Takeda Pharmaceutical Co. $TAK

Key Points

• Capital Research Global Investors raised its stake in Takeda Pharmaceutical by 0.8%, buying 108,556 shares to own 13,404,129 shares (about 0.42% of the company) worth roughly $196.24 million at quarter-end.
• Takeda reported quarterly EPS of $0.95, beating estimates by $0.40 but with revenue of $6.75 billion below expectations, and analysts remain mixed—MarketBeat’s average rating for the stock is Hold.

Capital Research Global Investors increased its stake in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 0.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,404,129 shares of the company's stock after purchasing an additional 108,556 shares during the quarter. Capital Research Global Investors owned 0.42% of Takeda Pharmaceutical worth $196,236,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of TAK. Bank of America Corp DE lifted its holdings in Takeda Pharmaceutical by 225.8% in the second quarter. Bank of America Corp DE now owns 1,037,163 shares of the company's stock valued at $16,035,000 after acquiring an additional 718,805 shares during the period. Goldman Sachs Group Inc. increased its holdings in Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company's stock valued at $79,120,000 after buying an additional 692,404 shares during the last quarter. ABC Arbitrage SA bought a new position in Takeda Pharmaceutical in the third quarter worth approximately $8,372,000. Quantinno Capital Management LP grew its position in shares of Takeda Pharmaceutical by 54.5% during the 2nd quarter. Quantinno Capital Management LP now owns 797,036 shares of the company's stock valued at $12,322,000 after acquiring an additional 280,992 shares during the period. Finally, Brandes Investment Partners LP increased its stake in shares of Takeda Pharmaceutical by 5.9% in the 2nd quarter. Brandes Investment Partners LP now owns 3,712,278 shares of the company's stock worth $57,392,000 after purchasing an additional 208,136 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on TAK shares. Weiss Ratings restated a "hold (c-)" rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. Morgan Stanley began coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They issued an "overweight" rating on the stock. Wall Street Zen upgraded Takeda Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research report on Saturday, January 31st. Finally, Zacks Research raised Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 3rd. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold".

Takeda Pharmaceutical Stock Performance

TAK stock opened at $18.12 on Thursday. The firm has a market cap of $57.64 billion, a price-to-earnings ratio of 75.48 and a beta of 0.01. Takeda Pharmaceutical Co. has a twelve month low of $12.99 and a twelve month high of $18.82. The business's fifty day simple moving average is $17.35 and its two-hundred day simple moving average is $15.52. The company has a quick ratio of 0.65, a current ratio of 1.19 and a debt-to-equity ratio of 0.56.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, January 29th. The company reported $0.95 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.40. The business had revenue of $6.75 billion for the quarter, compared to the consensus estimate of $7.81 billion. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. Analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited NYSE: TAK is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.